Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aeolus soars on US contract to develop treatment for lung acute radiation syndrome

This article was originally published in Scrip

Executive Summary

Aeolus Pharmaceuticals saw its shares ride a rollercoaster as the market digested the on news that the US Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), had awarded the company a contract worth up to $118.4 million for the advanced development of its catalytic antioxidant, AEOL 10150, as a medical countermeasure against radiation-inducted pulmonary injury. On 15 February, the day of the award, the company's shares gained $0.19 or 25% to $0.94 before closing the week back down at $0.65, valuing the company at $36.9 million.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts